These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32669219)

  • 21. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
    Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
    J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacists' nonprescription syringe dispensing perceptions and behaviors: A three-state descriptive analysis.
    Hagemeier NE; Dowling-McClay K; Baladezaei M; Curtis SJ; Spence M
    Drug Alcohol Depend; 2021 Apr; 221():108597. PubMed ID: 33631542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The opioid crisis: Origins, trends, policies, and the roles of pharmacists.
    Chisholm-Burns MA; Spivey CA; Sherwin E; Wheeler J; Hohmeier K
    Am J Health Syst Pharm; 2019 Mar; 76(7):424-435. PubMed ID: 31361827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
    DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
    Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
    Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
    J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
    Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
    J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Community pharmacist-provided opioid intervention frequencies and barriers.
    Nichols MA; Kepley KL; Rosko KS; Hudmon KS; Curran GM; Ott CA; Snyder ME; Miller ML
    J Am Pharm Assoc (2003); 2023; 63(1):336-342. PubMed ID: 36369075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using the theory of planned behavior to investigate community pharmacists' beliefs regarding engaging patients about prescription drug misuse.
    Fleming ML; Bapat SS; Varisco TJ
    Res Social Adm Pharm; 2019 Aug; 15(8):992-999. PubMed ID: 30442574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.
    Bach P; Hartung D
    Addict Sci Clin Pract; 2019 Sep; 14(1):30. PubMed ID: 31474225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Pharmacists in Safe Opioid Dispensing.
    Gregory T; Gregory L
    J Pharm Pract; 2020 Dec; 33(6):856-862. PubMed ID: 31256700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacist utilization of prescription opioid misuse interventions: Acceptability among pharmacists and patients.
    Riley TB; Alemagno S
    Res Social Adm Pharm; 2019 Aug; 15(8):986-991. PubMed ID: 30665825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescriber and pharmacist understanding of revised Rhode Island pain management regulations.
    Rogala BG; Jarvais A; Ng T; Bratberg J
    J Oncol Pharm Pract; 2021 Apr; 27(3):601-608. PubMed ID: 32517637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "The gatekeepers in prevention": Community pharmacist perceptions of their role in the opioid epidemic.
    Vadiei N; Eldridge LA; Meyerson BE; Agley J
    Subst Abus; 2022; 43(1):319-327. PubMed ID: 34214407
    [No Abstract]   [Full Text] [Related]  

  • 39. Improving Community Pharmacist-Delivered Care for Patients With Psychiatric Disorders Filling an Opioid Prescription.
    Werremeyer A; Frenzel O; Strand MA; Eukel H; Skoy E; Steig J
    Psychiatr Serv; 2022 Nov; 73(11):1294-1297. PubMed ID: 35502518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists.
    Lim JK; Bratberg JP; Davis CS; Green TC; Walley AY
    J Addict Med; 2016; 10(5):300-8. PubMed ID: 27261669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.